ABC Share Price | Cencora, Inc. Stock Analysis & Recommendation

Q: What does Cencora, Inc. do?

Overview:Cencora, Inc. is a pharmaceutical sourcing and distribution services company operating in the retailing industry, categorized as a large-cap entity.Financial Snapshot:- Most recent Net Sales: 75,454 Million (Quarterly Results - Mar 2025)- Most recent Net Profit: 717 Million (Quarterly Results - Mar 2025)- Market-cap: USD 81,057.12 Million (Large Cap)Key Metrics:- P/E: 44.00- Dividend Yield: 40.29%- Debt Equity: 5.67- Return on Equity: 177.43%- Price to Book: 80.03Contact Details:- Address: 1300 Morris Dr, CHESTERBROOK PA: 19087-5594- Tel: 1 610 7277000- Fax: 1 302 6555049

Q: Is Cencora, Inc. technically bullish or bearish?

As of 1 August 2025, the technical trend for Cencora, Inc. has changed from sideways to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish, indicating mixed signals across time frames. The daily moving averages are mildly bullish, supporting the overall positive trend. The Bollinger Bands show a sideways movement on the weekly chart but are mildly bullish on the monthly chart. The KST and Dow Theory indicate a mildly bearish stance on the weekly level but bullish on the monthly.In terms of performance, Cencora has outperformed the S&P 500 year-to-date with a return of 29.45% compared to the S&P 500's 12.22%. However, over the last week, the stock has declined by 3.95%, while the S&P 500 gained 1.05%. Overall, the current stance is mildly bullish, driven by monthly indicators and strong longer-term performance.

Q: Is Cencora, Inc. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. The company appears to be fairly valued based on its current metrics. Key ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is at a risky valuation with a P/E of 57.25.Cencora's stock has outperformed the S&P 500 across multiple periods, with a year-to-date return of 44.51% compared to the S&P 500's 13.30%. This strong performance reinforces the notion that the stock is fairly valued in the current market environment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

3.0 M

Shareholding (Dec 2025)

FII

22.24%

Held by 449 FIIs

DII

35.93%

Held by 64 DIIs

Promoter

0.02%

How big is Cencora, Inc.?

22-Jun-2025

As of Jun 18, Cencora, Inc. has a market capitalization of 81,057.12 million and net sales of 310,232.19 million with a net profit of 1,706.20 million for the latest four quarters. As of Sep 24, shareholder's funds are 645.94 million and total assets are 67,101.67 million.

View full answer

What does Cencora, Inc. do?

22-Jun-2025

Cencora, Inc. is a large-cap pharmaceutical sourcing and distribution services company with recent net sales of $75.454 billion and a net profit of $717 million. Key metrics include a P/E ratio of 44.00 and a dividend yield of 40.29%.

View full answer

Who are in the management team of Cencora, Inc.?

22-Jun-2025

As of March 2022, the management team of Cencora, Inc. includes Steven Collis (Chairman, President, CEO), Dr. Jane Henney (Lead Independent Director), and Directors Ornella Barra, D. Mark Durcan, Richard Gochnauer, and Lon Greenberg. They oversee the company's strategic direction and governance.

View full answer

Is Cencora, Inc. technically bullish or bearish?

20-Sep-2025

As of August 1, 2025, Cencora, Inc. shows a mildly bullish trend overall, supported by monthly indicators and strong year-to-date performance, despite a recent weekly decline.

View full answer

Is Cencora, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, Cencora, Inc. is fairly valued with a P/E ratio of 44, outperforming the S&P 500 with a year-to-date return of 44.51%, while its valuation metrics are more favorable compared to Boston Scientific and McKesson.

View full answer

Compare Cencora, Inc. with Similar Stocks

McKesson Corp.Boston Scientific Corp.Cardinal Health, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

High Management Efficiency with a high ROCE of 68.36%

Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.78 times

Healthy long term growth as Net Sales has grown by an annual rate of 11.19%

Flat results in Jun 25

With ROCE of 47.11%, it has a expensive valuation with a 12.67 Enterprise value to Capital Employed

Market Beating performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Retailing

Market cap

USD 95,865 Million (Large Cap)

P/E

34.00

Industry P/E

Dividend Yield

0.34%

Debt Equity

3.20

Return on Equity

147.64%

Price to Book

50.24

Revenue and Profits:

Net Sales:

85,932 Million

(Quarterly Results - Dec 2025)

Net Profit:

566 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-4.01%

6 Months

12.4%

1 Year

23.76%

2 Years

36.61%

3 Years

115.04%

4 Years

115.07%

5 Years

182.72%

Cencora, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

10.86%

EBIT Growth (5y)

11.80%

EBIT to Interest (avg)

12.09

Debt to EBITDA (avg)

0.78

Net Debt to Equity (avg)

5.67

Sales to Capital Employed (avg)

41.48

Tax Ratio

25.90%

Dividend Payout Ratio

27.63%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

68.36%

ROE (avg)

353.31%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

50.24

EV to EBIT

26.42

EV to EBITDA

20.81

EV to Capital Employed

12.71

EV to Sales

0.31

PEG Ratio

0.62

Dividend Yield

0.34%

ROCE (Latest)

48.12%

ROE (Latest)

147.64%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 184 Schemes (41.74%)

Foreign Institutions

Held by 449 Foreign Institutions (22.24%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 5.45% vs 12.78% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 14.66% vs -18.13% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "85,932.00",
          "val2": "81,487.10",
          "chgp": "5.45%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,265.60",
          "val2": "1,071.20",
          "chgp": "18.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "93.40",
          "val2": "61.20",
          "chgp": "52.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-233.30",
          "val2": "-78.40",
          "chgp": "-197.58%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "566.10",
          "val2": "493.70",
          "chgp": "14.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.70%",
          "val2": "9.70%",
          "chgp": "0.20%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2025 is 9.31% vs 12.12% in Sep 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2025 is 3.19% vs -12.31% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "321,332.80",
          "val2": "293,958.60",
          "chgp": "9.31%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "4,705.90",
          "val2": "4,151.80",
          "chgp": "13.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "419.80",
          "val2": "248.70",
          "chgp": "68.80%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1,054.60",
          "val2": "-827.00",
          "chgp": "-27.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,567.80",
          "val2": "1,519.30",
          "chgp": "3.19%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "11.40%",
          "val2": "10.30%",
          "chgp": "0.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

85,932.00

81,487.10

5.45%

Operating Profit (PBDIT) excl Other Income

1,265.60

1,071.20

18.15%

Interest

93.40

61.20

52.61%

Exceptional Items

-233.30

-78.40

-197.58%

Consolidate Net Profit

566.10

493.70

14.66%

Operating Profit Margin (Excl OI)

11.70%

9.70%

0.20%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 5.45% vs 12.78% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is 14.66% vs -18.13% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Sep'25

Sep'25

Sep'24

Change(%)

Net Sales

321,332.80

293,958.60

9.31%

Operating Profit (PBDIT) excl Other Income

4,705.90

4,151.80

13.35%

Interest

419.80

248.70

68.80%

Exceptional Items

-1,054.60

-827.00

-27.52%

Consolidate Net Profit

1,567.80

1,519.30

3.19%

Operating Profit Margin (Excl OI)

11.40%

10.30%

0.11%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Sep 2025 is 9.31% vs 12.12% in Sep 2024

Consolidated Net Profit

YoY Growth in year ended Sep 2025 is 3.19% vs -12.31% in Sep 2024

All Annual Results

Company CV

About Cencora, Inc.

Cencora, Inc.

Retailing

AmerisourceBergen Corporation is a pharmaceutical sourcing and distribution services company. The Company's segments include Pharmaceutical Distribution and Other. The Company provides services to healthcare providers, and pharmaceutical and biotech manufacturers. As of June 30, 2016, the Pharmaceutical Distribution segment consists of two operating segments, including the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG), which distributes specialty drugs to their customers. Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment's operations provide drug distribution and related services. The Other segment consists of the operations of various segments, including the AmerisourceBergen Consulting Services (ABCS), the World Courier Group, Inc. and the MWI Veterinary Supply, Inc. ABSG operates distribution facilities that focus primarily on complex disease treatment regimens.

Company Coordinates

Company Details

1300 Morris Dr , CHESTERBROOK PA : 19087-5594

Tel: 1 610 7277000

Registrar Details